EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Low Skeletal Muscle Radiodensity Predicts Response to CDK4/6 Inhibitors Plus Aromatase Inhibitors in Advanced Breast Cancer

Hyunwook Kim, Seungjin Baek, Sookyeong Han, Gun Min Kim, Joohyuk Sohn, Yumie Rhee, Namki Hong, Min Hwan Kim iD

Journal of Cachexia, Sarcopenia and Muscle · 2025

DOI: 10.1002/jcsm.13666 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, 2025. Verfasst von Hyunwook Kim und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea. Hauptthemen laut MEDLINE: Breast Neoplasms, Aromatase Inhibitors, Muscle, Skeletal, Cyclin-Dependent Kinase 4. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Severance Hospital Research Fund for Clinical Excellence (SHRC), Ministry of Health & Welfare, Republic of Korea, Korea government (Ministry of Science and ICT).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Recent evidence indicates that a dysregulated host metabolism influences treatment outcomes in patients with breast cancer. We investigated the association of computed tomography (CT)‐derived body composition indices with therapeutic responses in patients with hormone receptor‐positive, HER2‐negative advanced breast cancer (ABC) on endocrine plus CDK4/6 inhibitor (CDK4/6i) treatment.

Methods

The study involved a retrospective cohort of patients with ABC at the Yonsei Cancer Center who received CDK4/6i and aromatase inhibitors as first‐line therapy between January 2017 and October 2020. Body composition parameters were estimated from the non‐enhanced CT images of the third lumbar spine by commercialized deep learning software. Patients with low skeletal muscle radiodensity (SMD) were defined as patients with SMD of low tertile (≤ 28.7 Hounsfield Units). The primary outcome was progression‐free survival (PFS).

Results

Among the 247 female participants (median age, 53 years; mean body mass index [BMI], 23.7 kg/m 2 ), 45.7% had disease progression or death during a median follow‐up of 36.4 months. After adjusting for age and visceral metastasis, SMD was the only independent predictor among body composition parameters for worse PFS (adjusted hazard ratio [HR] = 1.20 per standard deviation decrement, 95% CI: 1.01–1.42, p = 0.041), whereas BMI, muscle area, and fat area were not. Participants with low SMD had a higher risk of progression than those without (PFS, 27.2 vs. 51.1 months, p = 0.009; adjusted HR 1.84, 95% CI: 1.22–2.76, p = 0.003). Strong associations between low SMD and poor PFS were observed in groups with pre‐menopause status (HR, 3.04 vs. 1.19 in post‐menopause; 95% CI: 1.54–5.99, p for interaction < 0.05) and without visceral metastases (HR, 2.95 vs. 1.19 in with visceral metastases; 95% CI: 1.59–5.49, p for interaction < 0.05).

Conclusions

CT‐defined low SMD predicts poor treatment outcomes in patients with ABC undergoing first‐line treatment with aromatase inhibitors and CDK4/6i.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsAromatase InhibitorsMuscle, SkeletalCyclin-Dependent Kinase 4HumansFemaleMiddle AgedAdultRetrospective StudiesAgedCyclin-Dependent Kinase 6Protein Kinase InhibitorsTreatment OutcomeNeoplasm Staging

Stichwörter der Autor:innen

CDK4/6 inhibitorsCT‐derived body compositionbreast cancerlow skeletal muscle radiodensitymuscle density

Substanzen

Aromatase InhibitorsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Protein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Internal Medicine, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
  • Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.
  • Endocrine Research Institute, Severance Hospital, Seoul, South Korea.
  • Department of Internal Medicine, Endocrine Research Institute, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.

ORCID-Profile: Min Hwan Kim

Förderung

  • Severance Hospital Research Fund for Clinical Excellence (SHRC)
  • Ministry of Health & Welfare, Republic of Korea
  • Korea government (Ministry of Science and ICT)

Zitieren

APA

Kim, H., Baek, S., Han, S., Kim, G. M., Sohn, J., Rhee, Y., Hong, N., & Kim, M. H. (2025). Low Skeletal Muscle Radiodensity Predicts Response to CDK4/6 Inhibitors Plus Aromatase Inhibitors in Advanced Breast Cancer. Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1002/jcsm.13666

Vancouver

Kim H, Baek S, Han S, Kim GM, Sohn J, Rhee Y, et al. Low Skeletal Muscle Radiodensity Predicts Response to CDK4/6 Inhibitors Plus Aromatase Inhibitors in Advanced Breast Cancer. Journal of Cachexia, Sarcopenia and Muscle. 2025. doi:10.1002/jcsm.13666

BibTeX
@article{Kim2025,
  author = {Kim, Hyunwook and Baek, Seungjin and Han, Sookyeong and Kim, Gun Min and Sohn, Joohyuk and Rhee, Yumie and Hong, Namki and Kim, Min Hwan},
  title = {Low Skeletal Muscle Radiodensity Predicts Response to CDK4/6 Inhibitors Plus Aromatase Inhibitors in Advanced Breast Cancer},
  journal = {Journal of Cachexia, Sarcopenia and Muscle},
  year = {2025},
  doi = {10.1002/jcsm.13666}
}
Kostenlos starten →